Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer

被引：4

作者：

Feng, Shuidong ^{[1
,2
]}

Ling, Hongyan ^{[3
]}

Guo, Hui ^{[4
]}

Tong, Lingling ^{[1
,2
]}

Hu, Guobin ^{[4
]}

Liao, Li ^{[1
,2
]}

Lv, Xueying ^{[1
,2
]}

Tan, Hongzhuan ^{[5
]}

Wu, Yimou ^{[6
]}

机构：

[1] Univ South China, Basic Med Postdoctoral Res Stn, Hengyang 421001, Peoples R China

[2] Univ South China, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Hengyang 421001, Peoples R China

[3] Univ South China, Sch Med, Dept Physiol, Hengyang 421001, Peoples R China

[4] Tumor Hosp Hunan Prov, Dept Pathol, Changsha 410008, Hunan, Peoples R China

[5] Cent S Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha 410008, Hunan, Peoples R China

[6] Univ South China, Sch Med, Dept Med Microbiol, Hengyang 421001, Peoples R China

来源：

JOURNAL OF THORACIC DISEASE | 2014年 / 6卷 / 05期

关键词：

ERBB2/HER2; mutation; non-small cell lung cancer (NSCLC); molecular; KINASE DOMAIN; EGFR; ADENOCARCINOMAS; GEFITINIB; THERAPY;

D O I：

10.3978/j.issn.2072-1439.2014.03.20

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

ERBB2 mutations have been reported to occur in a subset of patients with lung adenocarcinomas or lung squamous cell carcinomas for some ethnicities, but it is unclear for Chinese patients with lung squamous cell carcinomas up to now. We retrospectively evaluated the status of ERBB2 mutations in a large cross-sectional cohort of 212 Chinese patients with non-small cell lung cancer (NSCLC) diagnosed in several hospitals from southern China during a time period of 1.5 years by polymerase chain reaction (PCR)based direct sequencing and PCR-single strand conformation polymorphism (PCR-SSCP) analysis. ERBB2 mutation was found in 1 of 49 lung adenocarcinomas (2.0%) and none in lung squamous cell carcinomas and lung adenosquamous carcinomas. It implies the occurrence of ERBB2 mutations is infrequent in Chinese patients with NSCLC, especially in lung squamous cell carcinomas.

引用

页码：503 / 506

页数：4

共 14 条

[1]

[Anonymous], 2004, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs

[2] HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer [J].

Cappuzzo, F ;

Bemis, L ;

Varella-Garcia, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2619-2621

[3] ErbB receptors and signaling pathways in cancer [J].

Hynes, Nancy E. ;

MacDonald, Gwen .

CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (02) :177-184

[4] ERBB2 kinase domain mutation in the lung squamous cell carcinoma [J].

Lee, Jong Woo ;

Soung, Young Hwa ;

Kim, Su Young ;

Nam, Suk Woo ;

Park, Won Sang ;

Wang, Young Pil ;

Jo, Keon Hyun ;

Moon, Seok Whan ;

Song, Sang Yong ;

Lee, Jung Young ;

Yoo, Nam Jin ;

Lee, Sug Hyung .

CANCER LETTERS, 2006, 237 (01) :89-94

[5] Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains [J].

Li, Chenguang ;

Sun, Yihua ;

Fang, Rong ;

Han, Xiangkun ;

Luo, Xiaoyang ;

Wang, Rui ;

Pan, Yunjian ;

Hu, Haichuan ;

Zhang, Yang ;

Pao, William ;

Shen, Lei ;

Ji, Hongbin ;

Chen, Haiquan .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (01) :85-89

[6] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[7] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[8] EGFR and ErbB2 mutation status in Japanese lung cancer patients [J].

Sasaki, H ;

Shimizu, S ;

Endo, K ;

Takada, M ;

Kawahara, M ;

Tanaka, H ;

Matsumura, A ;

Iuchi, K ;

Haneda, H ;

Suzuki, E ;

Kobayashi, Y ;

Yano, M ;

Fujii, Y .

INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (01) :180-184

[9] Targeting the EGFR signaling pathway in cancer therapy [J].

Seshacharyulu, Parthasarathy ;

Ponnusamy, Moorthy P. ;

Haridas, Dhanya ;

Jain, Maneesh ;

Ganti, Apar K. ;

Batra, Surinder K. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (01) :15-31

[10] Somatic mutations of the HER2 kinase domain in lung adenocarcinomas [J].

Shigematsu, H ;

Takahashi, T ;

Nomura, M ;

Majmudar, K ;

Suzuki, M ;

Lee, H ;

Wistuba, I ;

Fong, KM ;

Toyooka, S ;

Shimizu, N ;

Fujisawa, T ;

Minna, JD ;

Gazdar, AF .

CANCER RESEARCH, 2005, 65 (05) :1642-1646

← 1 2 →